Prevalence and Course of IgA and IgG Antibodies against SARS-CoV-2 in Healthcare Workers during the First Wave of the COVID-19 Outbreak in Germany: Interim Results from an Ongoing Observational Cohort Study.
COVID-19
Germany
IgG response
SARS-CoV-2
anti-SARS-CoV-2 IgA
first wave
healthcare workers
seroprevalence
symptoms
Journal
Healthcare (Basel, Switzerland)
ISSN: 2227-9032
Titre abrégé: Healthcare (Basel)
Pays: Switzerland
ID NLM: 101666525
Informations de publication
Date de publication:
22 Apr 2021
22 Apr 2021
Historique:
received:
14
03
2021
revised:
18
04
2021
accepted:
20
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
(1) Background: Healthcare workers (HCWs) are prone to intensified exposure to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in the ongoing pandemic. We prospectively analyzed the prevalence of antibodies against SARS-CoV-2 in HCWs at baseline and follow up with regard to clinical signs and symptoms in two university hospitals in Brandenburg, Germany. (2) Methods: Screening for anti-SARS-CoV-2 IgA and IgG antibodies was offered to HCWs at baseline and follow up two months thereafter in two hospitals of Brandenburg Medical School during the first wave of the COVID-19 pandemic in Germany in an ongoing observational cohort study. Medical history and signs and symptoms were recorded by questionnaires and analyzed. (3) Results: Baseline seroprevalence of anti-SARS-CoV-2 IgA was 11.7% and increased to 15% at follow up, whereas IgG seropositivity was 2.1% at baseline and 2.2% at follow up. The rate of asymptomatic seropositive cases was 39.5%. Symptoms were not associated with general seropositivity for anti-SARS-CoV-2; however, class switch from IgA to IgG was associated with increased symptom burden. (4) Conclusions: The seroprevalence of antibodies against SARS-CoV-2 was low in HCWs but higher compared to population data and increased over time. Screening for antibodies detected a significant proportion of seropositive participants cases without symptoms.
Identifiants
pubmed: 33922198
pii: healthcare9050498
doi: 10.3390/healthcare9050498
pmc: PMC8144946
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Med Virol. 2020 Jun;92(6):568-576
pubmed: 32134116
Lancet Infect Dis. 2020 Dec;20(12):1401-1408
pubmed: 32758438
Clin Microbiol Infect. 2020 Dec;26(12):1670-1675
pubmed: 32911080
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
J Clin Virol. 2020 Aug;129:104468
pubmed: 32485620
JAMA. 2020 Mar 17;323(11):1092-1093
pubmed: 32031568
J Infect Dis. 2021 Jan 4;223(1):62-71
pubmed: 33175145
Eur J Immunol. 2020 Dec;50(12):2013-2024
pubmed: 33080068
Cochrane Database Syst Rev. 2020 Nov 20;11:CD006207
pubmed: 33215698
Pathology. 2020 Dec;52(7):764-769
pubmed: 33070955
J Infect Dis. 2021 Feb 24;223(4):589-599
pubmed: 33247924
JAMA. 2020 Aug 18;324(7):703-704
pubmed: 32663246
Am J Infect Control. 2020 Dec 19;:
pubmed: 33347937
Int J Infect Dis. 2021 Jan;102:63-69
pubmed: 33075539
Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
Quant Imaging Med Surg. 2020 Nov;10(11):2212-2214
pubmed: 33140000
Lancet. 2020 Apr 11;395(10231):1225-1228
pubmed: 32178769
Cochrane Database Syst Rev. 2020 Jun 25;6:CD013652
pubmed: 32584464
Nat Commun. 2020 Jul 6;11(1):3436
pubmed: 32632160
Occup Environ Med. 2020 Dec 9;:
pubmed: 33298533
Ann Intern Med. 2020 Sep 1;173(5):362-367
pubmed: 32491919
Clin Infect Dis. 2020 Jul 28;71(15):778-785
pubmed: 32198501
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288662
J Microbiol Immunol Infect. 2020 Jun;53(3):454-458
pubmed: 32205091
MMWR Morb Mortal Wkly Rep. 2020 Sep 04;69(35):1221-1226
pubmed: 32881855
Diagnostics (Basel). 2021 Jan 06;11(1):
pubmed: 33418886
Int J Infect Dis. 2021 Feb;103:381-388
pubmed: 33310021
Ann Intern Med. 2020 Jul 21;173(2):120-136
pubmed: 32369541